Targeted delivery of Epirubicin to cancer cells by PEGylated A10 aptamer

Journal of Drug Targeting

Volumn 21, Issue 8, 2013, Pages 739-744

  Taghdisi, Seyed Mohammad ^a   Danesh, Noor Mohammad ^b   Sarreshtehdar Emrani, Ahmad ^c   Tabrizian, Kaveh ^d   Zandkarimi, Majid ^d   Ramezani, Mohammad ^e   Abnous, Khalil ^f  

^a ZABOL UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b Institute of Chemical Science and Technology   (Iran)

^c MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Dept of Pharmacology and Toxicology   (Iran)

^e MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^f MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Aptamer; Chemotherapy; Epirubicin; Prostate cancer; Targeted delivery

Indexed keywords

A10 APTAMER; ANTHRACYCLINE DERIVATIVE; APTAMER; EPIRUBICIN; MACROGOL; MACROGOL EPIRUBICIN A10 APTAMER; PROSTATE SPECIFIC MEMBRANE ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; BONE MARROW SUPPRESSION; CANCER CELL; CANCER CELL CULTURE; CARDIOTOXICITY; CELL STRAIN LNCAP; CELL VIABILITY; COMPLEX FORMATION; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; DRUG DELIVERY SYSTEM; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG STABILITY; HUMAN; HUMAN CELL; INTERNALIZATION; MOLECULARLY TARGETED THERAPY; PRIORITY JOURNAL; PROSTATE CANCER;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; APTAMERS, NUCLEOTIDE; BENZENEACETAMIDES; CELL LINE, TUMOR; CELL SURVIVAL; DRUG DELIVERY SYSTEMS; EPIRUBICIN; HUMANS; MALE; PIPERIDONES; POLYETHYLENE GLYCOLS; PROSTATIC NEOPLASMS;

EID: 84883235384     PISSN: 1061186X     EISSN: 10292330     Source Type: Journal    
DOI: 10.3109/1061186X.2013.812095     Document Type: Article

References (36)

1. Xu R, Zhang Y, Ye X, et al. Inhibition effects and induction of apoptosis of flavonoids on the prostate cancer cell line PC-3 in vitro. Food Chem 2013;138: 48-53.
2. Oudard S. Progress in emerging therapies for advanced prostate cancer. Cancer Treat Rev 2013;39: 275-89.
3. Centenera MM, Fitzpatrick AK, Tilley WD, Butler LM. Hsp90: still a viable target in prostate cancer. Biochim Biophys Acta 2013; 1835: 211-18.
4. Duan S, Bleibel WK, Huang RS, et al. Mapping genes that contribute to daunorubicin-induced cytotoxicity. Cancer Res 2007; 67: 5425-33. (Pubitemid 46997283)
5. Chang YJ, Huang YP, Li ZL, Chen CH. GRP78 knockdown enhances apoptosis via the down-regulation of oxidative stress and akt pathway after epirubicin treatment in colon cancer DLD-1 cells. PLoS One 2012;7:e35123.
6. Petrioli R, Fiaschi AI, Pozzessere D, et al. Weekly epirubicin in patients with hormone-resistant prostate cancer. Br J Cancer 2002; 87: 720-5. (Pubitemid 35178748)
7. Petrioli R, Fiaschi AI, Francini E, et al. The role of doxorubicin and epirubicin in the treatment of patients with metastatic hormone-refractory prostate cancer. Cancer Treat Rev 2008;34: 710-18.
8. Betancourt T, Brown B, Brannon-Peppas L. Doxorubicin-loaded PLGA nanoparticles by nanoprecipitation: preparation, characterization and in vitro evaluation. Nanomedicine 2007;2: 219-32. (Pubitemid 46845768)
9. Jain KK. Editorial: targeted drug delivery for cancer. Technol Cancer Res Treatment 2005;4: 311-13. (Pubitemid 41242607)
10. Li DC, Zhong XK, Zeng ZP, et al. Application of targeted drug delivery system in Chinese medicine. J Control Release 2009;138: 103-12.
11. Bagalkot V, Farokhzad OC, Langer R, Jon S. An aptamerdoxorubicin physical conjugate as a novel targeted drug-delivery platform. Angew Chem Inter Edit 2006;45: 8149-52. (Pubitemid 44974149)
12. Huang YF, Shangguan D, Liu H, et al. Molecular assembly of an aptamer-drug conjugate for targeted drug delivery to tumor cells. ChemBioChem 2009;10: 862-8.
13. Taghdisi SM, Abnous K, Mosaffa F, Behravan J. Targeted delivery of daunorubicin to T-cell acute lymphoblastic leukemia by aptamer. J Drug Target 2010;18: 277-81.
14. Cao Z, Tong R, Mishra A, et al. Reversible cell-specific drug delivery with aptamer-functionalized liposomes. Angew Chem Inter Edit 2009;48: 6494-8.
15. Levy-Nissenbaum E, Radovic-Moreno AF, Wang AZ, et al. Nanotechnology and aptamers: applications in drug delivery. Trends Biotechnol 2008;26: 442-9.
16. Stoltenburg R, Reinemann C, Strehlitz B. SELEX-A (r)evolutionary method to generate high-affinity nucleic acid ligands. Biomol Eng 2007;24: 381-403. (Pubitemid 47391579)
17. Davis KA, Lin Y, Abrams B, Jayasena SD. Staining of cell surface human CD4 with 20-F-pyrimidine-containing RNA aptamers for flow cytometry. Nucl Acids Res 1998;26: 3915-24. (Pubitemid 28401340)
18. Cerchia L, Duconge F, Pestourie C, et al. Neutralizing aptamers from whole-cell SELEX inhibit the RET receptor tyrosine kinase. PLoS Biol 2005;3:e123.
19. Que-Gewirth NS, Sullenger BA. Gene therapy progress and prospects: RNA aptamers. Gene Therapy 2007;14: 283-91. (Pubitemid 46231922)
20. Blank M, Blind M. Aptamers as tools for target validation. Curr Opin Chem Biol 2005;9: 336-42. (Pubitemid 41019677)
21. Cerchia L, Esposito CL, Camorani S, et al. Coupling aptamers to short interfering RNAs as therapeutics. Pharmaceuticals 2011;4: 1434-49.
22. Meyer C, Hahn U, Rentmeister A. Cell-specific aptamers as emerging therapeutics. J Nucleic Acids 2011;2011:904750.
23. Bagalkot V, Zhang L, Levy-Nissenbaum E, et al. Quantum dot-aptamer conjugates for synchronous cancer imaging, therapy, and sensing of drug delivery based on Bi-fluorescence resonance energy transfer. Nano Lett 2007;7: 3065-70. (Pubitemid 350132931)
24. Ray P, White RR. Aptamers for targeted drug delivery. Pharmaceuticals 2010;3: 1761-78.
25. Tan L, Neoh KG, Kang ET, et al. PEGylated anti-MUC1 aptamerdoxorubicin complex for targeted drug delivery to MCF7 breast cancer cells. Macromol Biosci 2011;11: 1331-5.
26. Banerjee SS, Aher N, Patil R, Khandare J. Poly(ethylene glycol)- prodrug conjugates: concept, design, and applications. J Drug Deliv 2012;2012:103973.
27. Dhar S, Gu FX, Langer R, et al. Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug- PLGA-PEG nanoparticles. Proc Natl Acad Sci USA 2008;105: 17356-61.
28. Erdem A, Ozsoz M. Interaction of the anticancer drug epirubicin with DNA. Anal Chim Acta 2001;437: 107-14. (Pubitemid 32523002)
29. Vasir JK, Labhasetwar V. Targeted drug delivery in cancer therapy. Technol Cancer Res Treatment 2005;4: 363-74. (Pubitemid 41242611)
30. Zhu L, Huo Z, Wang L, et al. Targeted delivery of methotrexate to skeletal muscular tissue by thermosensitive magnetoliposomes. Int J Pharmaceutics 2009;370: 136-43.
31. Ye X, Yang D. Recent advances in biological strategies for targeted drug delivery. Cardiovasc Hematol Disorders - Drug Targets 2009; 9: 206-21.
32. Taghdisi SM, Lavaee P, Ramezani M, Abnous K. Reversible targeting and controlled release delivery of daunorubicin to cancer cells by aptamer-wrapped carbon nanotubes. Eur J Pharm Biopharm 2011;77: 200-6.
33. Keefe AD, Pai S, Ellington A. Aptamers as therapeutics. Nat Rev Drug Discov 2010;9: 537-50.
34. Bouchard PR, Hutabarat RM, Thompson KM. Discovery and development of therapeutic aptamers. Annu Rev Pharmacol Toxicol 2010;50: 237-57.
35. Jokerst JV, Lobovkina T, Zare RN, Gambhir SS. Nanoparticle PEGylation for imaging and therapy. Nanomedicine (Lond) 2011;6: 715-28.
36. Pai SS, Tilton RD, Przybycien TM. Poly(ethylene glycol)-modified proteins: implications for poly(lactide-co-glycolide)-based microsphere delivery. AAPS J 2009;11: 88-98.